Home / Uncategorised / Zelda Therapeutics links up with International Cannabis and Cannabinoids Institute
Zelda Therapeutics links up with International Cannabis and Cannabinoids Institute

Zelda Therapeutics links up with International Cannabis and Cannabinoids Institute


() has engaged the International Cannabis and Cannabinoids Institute (ICCI) to support its clinical trial programs in autism, opioid reduction and insomnia. 


This provides Zelda with an opportunity to collaborate with a panel of leading international medicinal cannabis experts.


The ICCI is an international centre of excellence for the advancement of cannabis and cannabinoid treatments.


The ICCI provides access to a global network of specialist services including expert advice on clinical study design and execution, requirements for regulatory approval, a full range of contract research services and direct liaison with study investigators.


READ: Zelda Therapeutics on track to report on multiple clinical trials


Zelda’s managing director Dr Richard Hopkins said: “We’re honoured to be working with the ICCI and Dr Ethan Russo, who are recognised globally as leading authorities on medicinal cannabis. Their insights will help inform and accelerate our clinical trial programs.


“Dr Russo and the ICCI will complement our existing medical advisory team and maintains Zelda’s strategy of engaging the world’s best medicinal cannabis researchers and clinicians.”


Dr Ethan Russo was recently appointed the Director of Research and Development at the ICCI.


He is a US-trained board-certified paediatric and adult neurologist, psychopharmacology researcher, former Medical Advisor to , and Medical Director of PHYTECS.


Dr Russo said: “I’m delighted to be collaborating with Zelda who is at the forefront of efforts to develop plant-derived cannabis medicines that have the potential to improve quality of life for patients.”


Progressing clinical and pre-clinical activities in 2019


Zelda remains on-track to report on the outcome from its clinical trials for insomnia, autism and opioid reduction by mid-2019.


The company is also continuing to assess opportunities to expand its clinical programs where they align with its strategic objectives.


Finally, Zelda is progressing discussions with third parties aiming at securing agreements to distribute clinically-validated Zelda products globally.


Full story is available here.

About Stoners

Check Also

Cannabis Canada Daily: Sundial’s pot reportedly returned after mould, rubber found - Article - BNN

Cannabis Canada Daily: Sundial’s pot reportedly returned after mould, rubber found – Article – BNN

CannTrust warns of possible ‘material hit’ amid probe  Embattled cannabis grower CannTrust Holdings warned in …

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.